Ligand Sells Promacta Assets and Royalty for $827 Million
Updates 2019 full-year financial guidance Conference call with slides to be held today at 5:00 p.m. Eastern time SAN DIEGO and NEW YORK (March 5, 2019) – Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Royalty Pharma announce the sale of Ligand’s Promacta®-related intellectual property